Barrington James Board & Executive Team Announce Troels Jordansen as New CEO at Yaqrit

Barrington James Board & Executive Partners are pleased to announce the appointment of Troels Jordansen as CEO of Yaqrit. 

Yaqrit is a clinical-stage company discovering and developing innovative treatments for patients with advanced liver disease at high risk of hospitalization and death. Yaqrit’s pipeline includes novel therapeutics in phase 2 / 3 clinical trials and two medical devices entering registrational trials providing acute and chronic treatments for advanced cirrhosis and acute-on-chronic liver failure, where there is an urgent need for more effective treatments.

Troels’s appointment is key in implementing the late clinical development and commercial strategy and realising the potential of Yaqrit’s portfolio. Troels brings a wealth of experience leading private and public listed companies, including fundraising, partnering and strategic planning and execution.

Troels Jordansen has been part of management teams raising over €200 million for public and private companies and closing deals valued at €500 million. Before joining Yaqrit, Mr Jordansen was CEO of Glycostem Therapeutics, overseeing fund-raising for clinical development in NK cell cancer therapies, manufacturing capabilities and licensing.

This appointment was made by the Barrington James Board & Executive Partners team, this search was led by Managing Partner, Adam J. Bloomfield.

Statements from Yaqrit Leadership:

Professor Rajiv Jalan, Yaqrit’s Founder and Interim CEO, stated:

“The appointment of Troels Jordansen as CEO is a key step for Yaqrit in assembling a powerful and experienced management team to realize the value of the pipeline of drugs and devices addressing unmet needs. Troels brings Yaqrit a great deal of experience in strategic planning and executing partnerships with companies developing complex advanced therapies.”

Troels Jordansen said:

“I am excited to join Yaqrit at this critical point in its development as an advanced liver disease company. Momentum is building in new Yaqrit: a broadening late-stage pipeline with multiple shots on goal, each supported by significant nondilutive grants, active business development, and an improving competitive environment. My first priority is to assemble an effective and experienced team working on clinical and corporate development.”